Osteolabs GmbH Secures Seed Funding to Commercialize Innovative Osteoporosis Diagnostic Test

VCBeat (WeChat ID: vcbeat) learned from foreign media that German biopharmaceutical company Osteolabs GmbH recently announced the completion of its seed funding round. The round was supported by MBG, Dr. Krause of MVZ Laboratories, and other unnamed angel investors. The proceeds will be used to further expand the company’s scale and advance the commercialization of a new patented testing method for osteoporosis.

Osteolabs GmbH, established in 2018 as a spin-off of the GEOMAR Helmholtz Centre for Ocean Research Kiel in Germany, is managed by its co-founder, Dr. Stefan Kloth, who serves as Managing Director. The company aims to successfully commercialize its patented diagnostic test for osteoporosis. This novel testing method enables early detection of osteoporosis using simple urine or blood samples. The protocol requires patients to provide a first-morning urine sample. Patients can perform the sampling at home and then send the specimen directly to the laboratory for analysis.

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mineral density and bone quality, deterioration of bone microarchitecture, and increased bone fragility, which predisposes individuals to fractures. This condition is most prevalent in women over the age of 50. Currently, conventional diagnosis of osteoporosis relies on X-ray technology, which poses potential radiation exposure risks to patients. Moreover, in most cases, osteoporosis cannot be diagnosed in advance.

Over the past few months, Osteolabs GmbH’s laboratory has achieved several key milestones, including securing patent protection for a novel assay and successfully completing its first clinical validation study. Furthermore, the results of this initial clinical validation have recently been published in a peer-reviewed journal.

“With this new funding, we will pursue broader commercialization of this novel assay in Germany. We have already successfully analyzed samples from the first cohort of patients,” said Dr. Stefan Kloth. “Based on feedback from recent scientific conferences, we are highly confident in this new testing method.”

MBG is a venture capital firm specializing in seed-stage investments, headquartered in Kiel, the capital of Schleswig-Holstein, Germany. To date, MBG has served over 600 companies, with an investment portfolio exceeding €100 million.

(Compiled by Zhang Xiaoxu)